Adraft of the new International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) was announced recently, and a panel of experts at the International Society of Oncology Pharmacy Practitioners (ISOPP) 2022 Virtual Symposium offered a preview of what the oncology community can expect from the document.
The speakers first underscored the need for such a document, given that chronic kidney disease (CKD) has a reported prevalence of up to 53% at cancer